Shuttle Pharmaceuticals (NASDAQ:SHPH) Stock Price Down 2.6% – Here’s What Happened

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) shares dropped 2.6% during mid-day trading on Tuesday . The company traded as low as $4.16 and last traded at $4.20. Approximately 47,203 shares changed hands during trading, a decline of 61% from the average daily volume of 121,820 shares. The stock had previously closed at $4.31.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on SHPH shares. Weiss Ratings reaffirmed a “sell (e)” rating on shares of Shuttle Pharmaceuticals in a research report on Saturday, September 27th. Wall Street Zen cut Shuttle Pharmaceuticals to a “strong sell” rating in a research note on Saturday, June 21st. One research analyst has rated the stock with a Sell rating, According to MarketBeat, Shuttle Pharmaceuticals has an average rating of “Sell”.

Shuttle Pharmaceuticals Stock Down 2.6%

The firm has a 50-day moving average of $3.67 and a two-hundred day moving average of $5.08. The company has a market capitalization of $4.49 million, a PE ratio of -1.01 and a beta of -1.01.

About Shuttle Pharmaceuticals

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .